Bio-Technology General Corp. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference.Business Editors/Health/Medical Writers BIOWIRE2K EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--May 28, 2003 Bio-Technology General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced that Christopher G. Clement, President and COO, will present at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg Global Specialty Pharmaceuticals Conference on Thursday June 5, 2003 at 9:00 am EST EST electroshock therapy. EST abbr. electroshock therapy at the Grand Hyatt New York. The public is invited to participate through the UBS Warburg web site at www.ubswarburg.com. A replay will be available starting on June 5, 2003 at 1:00 pm EST until July 3, 2003. A link to the live conference and replay will be available on the Company's web site at www.btgc.com. About Bio-Technology General Corp. Bio-Technology General Corp. is a biopharmaceutical company with a portfolio of specialty pharmaceutical products and expertise in developing, manufacturing, and marketing human health care products. Products marketed by BTG's sales force in the United States are Oxandrin(R) (oxandrolone, USP USP - unique sales point ) and Delatestryl(R) (testosterone enanthate). BTG's UK subsidiary, Rosemont Pharmaceuticals, Limited, develops, manufactures, and markets oral liquid formulations of prescription products for the UK pharmaceutical market through its own sales force. BTG's Israeli subsidiary, Bio-Technology General, Ltd., manufactures and markets in Israel Bio-Tropin(TM) (recombinant human growth hormone human growth hormone (HGH): see growth hormone. ), BioLon(TM) (sodium hyaluronate hyaluronate /hy·al·uro·nate/ (hi?ah-ldbobr´ro-nat) a salt, anion, or ester of hyaluronic acid. The sodium salt and a derivative of it are used as analgesics in the treatment of osteoarthritis of the knee. ), Bio-Hep-B(R) (hepatitis B vaccine hepatitis B vaccine n. Abbr. HB A vaccine prepared from the inactivated surface antigen of the hepatitis B virus and used to immunize against hepatitis B. ), and Arthrease(TM) (sodium hyaluronate for osteoarthritis). Products marketed by BTG's licensees are Mircette(R) (oral contraceptive), and BioLon(TM) in the United States, and Bio-Tropin(TM), BioLon(TM), Bio-Hep-B(R), Silkis(R) (vitamin D derivative), Arthrease(TM), and recombinant human insulin Noun 1. recombinant human insulin - a form of insulin (trade name Humulin) made from recombinant DNA that is identical to human insulin; used to treat diabetics who are allergic to preparations made from beef or pork insulin Humulin , in international markets. BTG's news releases and other information are available on the Company's website at www.btgc.com. Arthrease is a trademark of DePuy Orthopaedics, Inc.; Mircette is a registered trademark of Organon, Inc.; Silkis is a registered trademark of Galderma. Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, development, introduction, or consumer acceptance of competing products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion